Tango Therapeutics IncTNGX
Price$24.45Intrinsic value$10.2858% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $53.8M+27.9% YoYTTM through 30 Jun 2026
Net Income -$123.7MTTM through 30 Jun 2026
Free Cash Flow -$144.2MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%
EBITDA Margin-249.0%
Operating Margin-253.4%
Net Margin-229.9%

Returns

-11.6%ROE
-11.5%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio16.30x
Net Debt-$379.8Mnet cash position
Cash & Equivalents$345.6M

Quality Metrics

Altman Z-Score52.18
Piotroski F-Score2 / 9
FCF Margin-268.1%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'20'21'22'23'24'25
FY2025: $62.4M
Diluted EPS-$0.84TTM
'21'22'23'24'25
FY2025: $-0.87

Dividend

No dividend

Capital Allocation

Capex Intensity0.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.